Descartes-08 is under clinical development by Cartesian Therapeutics and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase II drugs for Myasthenia Gravis have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Descartes-08’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Descartes-08 is under development for the treatment of multiple myeloma (third-line therapy) and myasthenia gravis. The therapeutic candidate consists of T cells modified by mRNA to express chimeric antigen receptors (CAR T-cells). It acts by targeting BCMA. It is developed based on CAR-T cell technology.
Cartesian Therapeutics overview
Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies designed to benefit the wide range of patients with cancer, autoimmune diseases, and respiratory diseases. Cartesian Therapeutics is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of Descartes-08’s drug-specific PTSR and LoA scores, buy the report here.